Differential behavior of NF-B, IB and EGFR during the renal carcinogenic process in an experimental model in vivo

Renal cell carcinoma (RCC) is the most common type of cancer of the adult kidney. It is generally asymptomatic even at advanced stages, so opportune diagnosis is rare, making it almost impossible to study this cancer at its early stages. RCC tumors induced by ferric nitrilotriacetate (FeNTA) in rats histologically correspond to the human clear cell RCC subtype (ccRCC) and the exposure to this carcinogen during either one or two months leads to different early stages of neoplastic development. High levels of nuclear factor kappa B (NF-kappa B) and epidermal growth factor receptor (EGFR) as well as low levels of NF-kappa B inhibitor alpha (I kappa B alpha) are frequent in human RCC, but their status in FeNTA-induced tumors and their evolution along renal carcinogenesis is unclear. On this basis, in the present study NF-kappa B, I kappa B alpha and EGFR behavior was analyzed at different stages of the experimental renal carcinogenesis model. Similar to patients with RCC, neoplastic tissue showed high levels of p65, one of the predominant subunits of NF-kappa B in ccRCC and of EGFR (protein and mRNA), as well as a decrease in the levels of NF-kappa B's main inhibitor, I kappa B alpha, resulting in a classic oncogenic combination. Conversely, different responses were observed at early stages of carcinogenesis. After one month of FeNTA-exposure, NF-kappa B activity and EGFR levels augmented; but unexpectedly, I kappa B alpha also did. While after two months, NF-kappa B activity diminished, but EGFR and I kappa B alpha levels remained elevated. In conclusion, FeNTA-induced tumors and RCC human neoplasms are analogues regarding to the classic NF-kappa B, I kappa B alpha and EGFR behavior, and distinctive non-conventional combination of changes is developed at each early stage studied. The results obtained suggest that the dysregulation of the analyzed molecules could be related to different signaling pathways and therefore, to particular effects depending on the phase of the carcinogenic process.